CANbridge Life Sciences Submits Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) in China

Dec 21, 2017

CANbridge Completes Patient Enrolment for Phase I Clinical Trial of CAN008 in Treatment of Glioblastoma Multiforme in Taiwan

Nov 30, 2017

CAN008 Injection for the Treatment of Gbm China Taiwan Phase I Data Releasing

Nov 02, 2017

James Xue is Appointed to Leadership and Development Council Member

Sep 26, 2017

CANbridge Life Sciences Appoints Chief Business Officer Will Head First US Office

Sep 12, 2017

CANbridge Congratulates Apogenix APG101 Receiving Ema “Prime” Designation

Jul 26, 2017

CANbridge Submits Ind Application for CAN008 PHII/III Trial in GBM in China

Jul 18, 2017

James Xue, Founder and CEO of CANbridge, Present at 2017 China GCP Conference

Jun 08, 2017

James Xue, Founder and CEO of CANbridge, Present at 2017 Boston CEO Conference

Jun 01, 2017